

For release: 20 April 2009

EPISTEM PRESENT AT AACR MEETING IN DENVER

MANCHESTER, UNITED KINGDOM - Epistem plc (LSE: EHP), the UK biotechnology and contract research company, have presented results from their latest plucked hair biomarker study at the AACR Meeting in Denver, Colorado on Sunday 19th April. The study was to determine the specific response to oral administration of Erlotinib, the epidermal growth factor receptor (EGFR) inhibitor, in a plucked hair preclinical model. The data itself is impressive and endorses the utility of the plucked hair model.

In addition to tracking the gene expression and molecular pathway change through the preclinical and clinical development of a drug, the Erlotinib results open up the possibility for clinicians to monitor patient specific gene responses to treatment, enabling an early indication that the treatment will be successful. As this diagnostic procedure is minimally invasive, patients will be able to undergo frequent testing to confirm that the targeted gene expression changes are correlating with the oncology treatment protocol being used therefore predictive of a successful outcome.

The results presented support the thesis that the plucked hair biomarker platform provides a simple, minimally invasive means of monitoring the specific response of epithelial tissue to oncology agents targeted to discrete signaling pathways. This data has been generated using the established oncology agent, Erlotinib, which is used widely to treat advanced non small cell lung cancer and in combination for pancreatic cancer. It is also being researched for other indications. Together with previous human and preclinical results, this data showed that effective levels of RNA can be obtained for gene expression measurement.

The abstract will be available on request following the presentation.

For further information on the Company, please visit www.epistem.co.uk or contact:

Lydia Meyer Turkson	+44 (0)161 606 7258
Biomarker Director	
Epistem plc.	info@epistem.co.uk

Mike Wort / Anna Dunphy	+44 (0) 207 861 3838
Financial PR/IR	
De Facto Communications	